147 related articles for article (PubMed ID: 20001558)
1. Novel TNF antagonists for the treatment of rheumatoid arthritis.
Statkute L; Ruderman EM
Expert Opin Investig Drugs; 2010 Jan; 19(1):105-15. PubMed ID: 20001558
[TBL] [Abstract][Full Text] [Related]
2. Tumour necrosis factor α antagonists in the treatment of rheumatoid arthritis: an immunological perspective.
Meroni PL; Valesini G
BioDrugs; 2014 Apr; 28 Suppl 1():S5-13. PubMed ID: 24687234
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice.
Punzi L; Lapadula G; Mathieu A
BioDrugs; 2014 Apr; 28 Suppl 1():S25-37. PubMed ID: 24687236
[TBL] [Abstract][Full Text] [Related]
4. Certolizumab pegol: a new biologic targeting rheumatoid arthritis.
Patel AM; Moreland LW
Expert Rev Clin Immunol; 2010 Nov; 6(6):855-66. PubMed ID: 20979550
[TBL] [Abstract][Full Text] [Related]
5. The clinical efficacy and safety of certolizumab pegol in rheumatoid arthritis.
Fleischmann R
Expert Opin Biol Ther; 2010 May; 10(5):773-86. PubMed ID: 20230188
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
[TBL] [Abstract][Full Text] [Related]
7. Aspects of TNF inhibitor therapy in rheumatoid arthritis.
Nam J; Emery P
Mod Rheumatol; 2010 Aug; 20(4):325-30. PubMed ID: 20195684
[TBL] [Abstract][Full Text] [Related]
8. RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis.
Ramiro S; van Tubergen AM; Landewé RB
Expert Rev Clin Immunol; 2010 Sep; 6(5):713-20. PubMed ID: 20828279
[TBL] [Abstract][Full Text] [Related]
9. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol.
Pasut G
BioDrugs; 2014 Apr; 28 Suppl 1():S15-23. PubMed ID: 24687235
[TBL] [Abstract][Full Text] [Related]
10. TNF-α antagonists beyond approved indications: stories of success and prospects for the future.
Karampetsou MP; Liossis SN; Sfikakis PP
QJM; 2010 Dec; 103(12):917-28. PubMed ID: 20802008
[TBL] [Abstract][Full Text] [Related]
11. Certolizumab pegol: in rheumatoid arthritis.
Duggan ST; Keam SJ
BioDrugs; 2009; 23(6):407-17. PubMed ID: 19894782
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.
Fleischmann R; Vencovsky J; van Vollenhoven RF; Borenstein D; Box J; Coteur G; Goel N; Brezinschek HP; Innes A; Strand V
Ann Rheum Dis; 2009 Jun; 68(6):805-11. PubMed ID: 19015206
[TBL] [Abstract][Full Text] [Related]
13. How FABulous is PEGgy? Certoliziumab pegol from the bench to the patients.
Aletaha D
BioDrugs; 2014 Apr; 28 Suppl 1():S3-4. PubMed ID: 24687233
[No Abstract] [Full Text] [Related]
14. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis.
Launois R; Avouac B; Berenbaum F; Blin O; Bru I; Fautrel B; Joubert JM; Sibilia J; Combe B
J Rheumatol; 2011 May; 38(5):835-45. PubMed ID: 21239748
[TBL] [Abstract][Full Text] [Related]
15. Certolizumab pegol.
Goel N; Stephens S
MAbs; 2010; 2(2):137-47. PubMed ID: 20190560
[TBL] [Abstract][Full Text] [Related]
16. Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety.
Mease PJ
Rheumatology (Oxford); 2011 Feb; 50(2):261-70. PubMed ID: 20871129
[TBL] [Abstract][Full Text] [Related]
17. [Certolizumab pegol].
Delgado Frías E; Díaz González JF
Reumatol Clin; 2011 Mar; 6S3():S7-11. PubMed ID: 21794764
[TBL] [Abstract][Full Text] [Related]
18. Certolizumab: efficacy and safety profile of a novel pegylated TNF-alpha blocking agent.
Lubrano E; Spadaro A
Acta Biomed; 2011 Apr; 82(1):26-34. PubMed ID: 22069953
[TBL] [Abstract][Full Text] [Related]
19. Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection.
Caso F; Cantarini L; Morisco F; Del Puente A; Ramonda R; Fiocco U; Lubrano E; Peluso R; Caso P; Galeazzi M; Punzi L; Scarpa R; Costa L
Expert Opin Biol Ther; 2015 May; 15(5):641-50. PubMed ID: 25652590
[TBL] [Abstract][Full Text] [Related]
20. Certolizumab pegol in rheumatoid arthritis: current update.
Fechtenbaum M; Md Yusof MY; Emery P
Expert Opin Biol Ther; 2014 Jun; 14(6):841-50. PubMed ID: 24654999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
